Drug Rehab: Frequently Asked Questions
Drug rehabilitation is one of those subjects where the gap between what people think they know and what actually happens inside a treatment program can be genuinely wide. These questions address the practical realities of rehab — how it's structured, what drives placement decisions, where the confusing parts tend to cluster, and which sources are worth trusting when the stakes are high.
What should someone know before engaging?
The single most useful thing to understand before any conversation with a treatment provider is that drug rehab is not one thing. It's a category that spans medically supervised detox lasting 5–7 days, short-term residential programs of 28–30 days, long-term therapeutic communities running 6–12 months, and outpatient structures where someone sleeps at home and attends treatment for 9 to 20 hours per week. Knowing roughly which tier fits a given situation before making calls saves a significant amount of confusion.
It also helps to know that the word "rehab" carries no legal definition at the federal level. What it describes varies by state licensure requirements and by which clinical model a facility uses. The home page of this resource is a good place to orient before diving into specific program types.
What does this actually cover?
Drug rehabilitation broadly covers clinical and behavioral interventions designed to address substance use disorders — a diagnostic category defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) published by the American Psychiatric Association. That definition matters because it shapes insurance coverage, clinical assessment tools, and how treatment outcomes are measured. The field covers alcohol, opioids, stimulants, cannabis, sedatives, and polysubstance combinations, each of which tends to require somewhat different medical protocols, particularly during withdrawal.
What are the most common issues encountered?
Three friction points come up repeatedly. First, insurance authorization battles: coverage under the Mental Health Parity and Addiction Equity Act (MHPAEA, 29 U.S.C. § 1185a) requires that insurers apply no stricter limits to substance use treatment than to comparable medical or surgical benefits — but prior authorization denials remain common, and appeals are often necessary. Second, waitlists for publicly funded beds: SAMHSA's 2022 National Survey on Drug Use and Health reported that roughly 94% of people aged 12 or older who needed substance use treatment did not receive it at a specialty facility, a figure that reflects both access barriers and self-selection. Third, co-occurring mental health conditions: anxiety, depression, and trauma histories frequently accompany substance use disorders, and programs that treat only the addiction without addressing underlying conditions show lower long-term retention rates.
How does classification work in practice?
The most widely used classification framework in the United States is the ASAM Criteria — produced by the American Society of Addiction Medicine — which places patients along six dimensions (acute intoxication, biomedical conditions, emotional/behavioral/cognitive conditions, readiness to change, relapse potential, and recovery environment) and assigns them to one of five broad levels of care: Level 0.5 through Level 4. A clinician conducts the multidimensional assessment and recommends the least intensive level at which treatment can safely occur. This is a clinical judgment call, not a formula, which is why two clinicians can sometimes land on different recommendations for the same patient.
What is typically involved in the process?
A standard treatment episode moves through four recognizable phases:
- Assessment and intake — structured clinical interview, medical history, drug screening, ASAM-level determination
- Detoxification (when indicated) — medically monitored withdrawal, often 5–10 days depending on substance and severity; not available at all facilities
- Primary treatment — individual therapy, group therapy, psychoeducation, and medication-assisted treatment (MAT) where appropriate; FDA-approved medications include buprenorphine, methadone, and naltrexone for opioid use disorder
- Continuing care and aftercare — step-down to lower levels of care, outpatient check-ins, peer support, and recovery housing referrals
The handoff between phases — particularly the transition from residential to outpatient — is where relapse risk spikes. Programs with structured transition planning show meaningfully better outcomes than those that discharge without a documented continuing care plan.
What are the most common misconceptions?
The most durable misconception is that someone has to "hit rock bottom" before treatment can work. Research published by NIDA (the National Institute on Drug Abuse, now NIDA under NIH) consistently shows that treatment initiated under external pressure — family intervention, court order, employer mandate — produces outcomes comparable to self-initiated treatment. Motivation is malleable; it often develops during treatment rather than being a prerequisite for it.
A second persistent myth is that detox alone constitutes treatment. Medical detox clears substances from the body; it does not address the behavioral, psychological, or environmental factors that drive use. Without follow-on treatment, relapse rates after detox-only episodes are high.
Where can authoritative references be found?
Four federal and professional bodies produce the most reliable primary-source material:
- SAMHSA (samhsa.gov) — publishes the National Survey on Drug Use and Health, the Treatment Episode Data Set (TEDS), and clinical guidelines
- NIDA (nida.nih.gov) — maintains evidence-based research on treatment effectiveness and drug-specific pharmacology
- ASAM (asam.org) — publishes the ASAM Criteria and clinical practice guidelines
- FDA (fda.gov) — maintains the authoritative list of approved medications for substance use disorders
State-level licensing boards and behavioral health agencies are the correct sources for jurisdiction-specific facility standards.
How do requirements vary by jurisdiction or context?
Significantly. State behavioral health agencies set licensing standards for treatment facilities, and those standards differ on staffing ratios, required services, physical plant specifications, and mandatory reporting. California's Department of Health Care Services, for instance, operates a separate certification process for narcotic treatment programs (methadone clinics) that runs parallel to general residential licensure. In rural states, certificate-of-need laws can limit the number of licensed beds in a region regardless of clinical demand. Criminal justice–involved individuals may face court-mandated program lengths or provider restrictions that override clinical recommendations. Insurance context also matters: Medicaid-funded treatment, private insurance, and self-pay arrangements each create different authorization requirements and covered service arrays.